Naiem T. Issa, MD, PhD: Real-World Use of Tapinarof Cream 1% Once Daily in Patients with Seborrheic Dermatitis: A Case Series

​Dr. Naiem T. Issa presents a case series on the real-world application of Tapinarof Cream 1% once daily in patients with seborrheic dermatitis, highlighting its efficacy and safety profile in clinical practice.

Topics Covered:

  • Tapinarof Cream 1% usage in seborrheic dermatitis​
  • Efficacy outcomes in real-world settings​
  • Safety profile assessment​

Explore Related Resources:

Seborrheic Dermatitis Archives

New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis

MORE JOURNAL REVIEWS

Journal Review: Andrew Blauvelt

Andrew Blauvelt, MD, MBA, a dermatologist at the Oregon Medical Research Center in Portland, Oregon, discusses the impact Ruxolitinib cream has on itch in patients...

PLAY

Journal Review: Linda Stein Gold

Linda Stein Gold, MD, discusses an article published in the Journal of Drugs in Dermatology titled, "Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe...

PLAY

Dr. Dasilva discusses his article published in JCAD September 2025, titled “Nemolizumab Demonstrates Marked Efficacy in Challenging Chronic Pruritus: A Real-world Multicenter Case Series.” Read

Dr. Graber discusses her article published in JCAD January 2025, titled “Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl

Dr. Nada Elbuluk presents findings on how outpatient dermatology patients use the internet and social media to acquire dermatology-related information. Topics Covered: Patient behavior in

Dr. Tina Bhutani reviews real-world data showing improved patient-reported outcomes and satisfaction with tildrakizumab in moderate-to-severe plaque psoriasis. Topics Covered: Tildrakizumab 100mg over 64 weeks

Alice Gottlieb, MD, PhD, discusses a new article published in the October 2024 issue of JCAD that sought to correlate the time lag between psoriatic

James Del Rosso, DO, Clinical Editor-in-Chief of JCAD, discusses a new review article published in the August 2024 issue of JCAD, titled “Clindamycin: A Comprehensive

Andrew Blauvelt, MD, MBA, a dermatologist at the Oregon Medical Research Center in Portland, Oregon, discusses the impact Ruxolitinib cream has on itch in patients
Linda Stein Gold, MD, discusses an article published in the Journal of Drugs in Dermatology titled, "Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe
Valerie Callender, MD, is the Founder and Medical Director of the Callender Dermatology & Cosmetic Center, and is known for her sensitive and cutting-edge approach
Nanette Silverberg, MD, a Clinical Professor of Pediatrics and Dermatology at the Icahn School of Medicine at Mount Sinai in New York, New York, provides
Sabrina Fabi, MD, discusses the article, “Customized Treatment Using Microfocused Ultrasound with Visualization for OptimizedPatient Outcomes: A Review of Skin-tightening Energy Technologies and a Pan-Asian